Translational molecular imaging in exocrine pancreatic cancer

Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma (PDAC), which makes up more than 95% of all pancreatic cancers. Late diagnosis and failure of chemotherapy and radiotherapy are all too common, and many patients die soon aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornelissen, Bart, Knight, James C., Mukherjee, Somnath, Evangelista, Laura, Xavier, Catarina, Caobelli, Federico, Del Vecchio, Silvana, Rbah-Vidal, Latifa, Barbet, Jacques, de Jong, Marion, van Leeuwen, Fijs W. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208802/
https://www.ncbi.nlm.nih.gov/pubmed/30225616
http://dx.doi.org/10.1007/s00259-018-4146-5
Descripción
Sumario:Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma (PDAC), which makes up more than 95% of all pancreatic cancers. Late diagnosis and failure of chemotherapy and radiotherapy are all too common, and many patients die soon after diagnosis. Here, we make the case for the increased use of molecular imaging in PDAC preclinical research and in patient management.

Ejemplares similares